Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present
at the 161st American Psychiatric Association annual meeting the results of
a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the
treatment of acute agitation in schizophrenic patients.


Alexza Pharmaceuticals is an emerging specialty pharmaceutical company
focused on the development and commercialization of novel, proprietary
products for the treatment of acute and intermittent conditions. The
Company's technology, the Staccato system, vaporizes unformulated drug to
form a condensation aerosol that allows rapid systemic drug delivery
through deep lung inhalation. The drug is quickly absorbed through the
lungs into the bloodstream, providing speed of therapeutic onset that is
comparable to intravenous administration, but with greater ease, patient
comfort and convenience.



Alexza has six product candidates in clinical development. Alexza's
lead program, AZ-004 (Staccato loxapine) for the treatment of acute
agitation in schizophrenic or bipolar disorder patients, is in Phase 3
testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of
migraine headaches has completed Phase 2 testing. AZ-104 (Staccato
loxapine) for the acute treatment of migraine headaches and AZ-002
(Staccato alprazolam) for the acute treatment of panic attacks associated
with panic disorder are in Phase 2 testing. Product candidates in Phase 1
testing include AZ-003 (Staccato fentanyl) for the treatment of
breakthrough pain, which is partnered with Endo Pharmaceuticals in North
America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More
information, including this and past press releases from Alexza is
available online at http://www.alexza.com.



Safe Harbor Statement




The anticipated poster presentation will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of
1995, and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those inherent in
the process of developing and commercializing drugs. The Company's
forward-looking statements also involve assumptions that, if they prove
incorrect, would cause its results to differ materially from those
expressed or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional detail in
the Company's Annual Report on Form 10-K for the year ended December 31,
2007, and the Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements contained in
the poster presentation are made as of their date of presentation, and the
Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.


Alexza Pharmaceuticals, Inc.

http://www.alexza.com